Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CFO Sells $39,616.81 in Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.29, for a total value of $39,616.81. Following the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. The trade was a 5.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Rocket Pharmaceuticals Price Performance

Shares of RCKT traded up $0.33 during mid-day trading on Friday, hitting $5.27. 5,069,673 shares of the company traded hands, compared to its average volume of 1,230,549. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $561.94 million, a price-to-earnings ratio of -1.92 and a beta of 1.00. The business has a 50-day moving average of $8.38 and a 200 day moving average of $12.09. Rocket Pharmaceuticals, Inc. has a one year low of $4.55 and a one year high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06. As a group, equities analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They set an "outperform" rating and a $32.00 price target for the company. Canaccord Genuity Group cut their target price on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. BMO Capital Markets began coverage on Rocket Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target on the stock. Chardan Capital cut their price objective on Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating for the company in a report on Friday, February 28th. Finally, Scotiabank upped their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its holdings in Rocket Pharmaceuticals by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 569,814 shares of the biotechnology company's stock valued at $10,524,000 after purchasing an additional 20,322 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Rocket Pharmaceuticals by 9.1% during the third quarter. The Manufacturers Life Insurance Company now owns 152,293 shares of the biotechnology company's stock worth $2,813,000 after purchasing an additional 12,680 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Rocket Pharmaceuticals by 9.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,767 shares of the biotechnology company's stock valued at $347,000 after buying an additional 1,675 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Rocket Pharmaceuticals by 1.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company's stock valued at $2,210,000 after buying an additional 1,561 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in Rocket Pharmaceuticals during the 3rd quarter worth $290,000. Institutional investors and hedge funds own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.